Endocannabinoids: some like it fat (and sweet too).

  title={Endocannabinoids: some like it fat (and sweet too).},
  author={Isabelle Matias and Luigia Cristino and Vincenzo Di Marzo},
  journal={Journal of neuroendocrinology},
  volume={20 Suppl 1},
There is growing interest in the commercialisation of the CB(1) receptor antagonist Rimonabant in Europe for the treatment of obesity and the metabolic syndrome. Clinical trials have shown that CB(1) receptor blockers are able to reduce not only food intake but also abdominal adiposity and its metabolic sequelae. Accordingly, CB(1) receptors, and tissue concentrations of endocannabinoids sufficient to activate them, are present in all brain and peripheral organs involved in the control of… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…